BR100 Increased By (0.27%)
BR30 Increased By (0.15%)
KSE100 Increased By (0.15%)
KSE30 Increased By (0.01%)
BECO 5.92 Decreased By ▼ -0.11 (-1.82%)
BML 57.31 Increased By ▲ 4.56 (8.64%)
BOP 34.09 Decreased By ▼ -0.16 (-0.47%)
CNERGY 8.20 Increased By ▲ 0.04 (0.49%)
DCL 12.15 Decreased By ▼ -0.19 (-1.54%)
FCCL 53.88 Decreased By ▼ -0.01 (-0.02%)
FCSC 5.25 Increased By ▲ 0.03 (0.57%)
FFL 18.01 Decreased By ▼ -0.02 (-0.11%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.23 Increased By ▲ 0.23 (2.09%)
KEL 8.17 Increased By ▲ 0.06 (0.74%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.79 Increased By ▲ 0.74 (0.84%)
NBP 186.50 Increased By ▲ 0.02 (0.01%)
PACE 10.96 Increased By ▲ 0.24 (2.24%)
PAEL 40.42 Increased By ▲ 0.48 (1.2%)
PIAHCLA 26.26 Increased By ▲ 0.09 (0.34%)
PIBTL 17.33 Increased By ▲ 0.01 (0.06%)
PPL 232.00 Decreased By ▼ -0.78 (-0.34%)
PRL 34.70 Decreased By ▼ -0.25 (-0.72%)
PTC 66.80 Decreased By ▼ -0.76 (-1.12%)
SEARL 91.45 Increased By ▲ 0.52 (0.57%)
SSGC 27.15 Decreased By ▼ -0.02 (-0.07%)
TELE 8.70 Increased By ▲ 0.13 (1.52%)
THCCL 65.35 Increased By ▲ 5.22 (8.68%)
TPLP 9.20 Increased By ▲ 0.44 (5.02%)
TREET 24.55 Increased By ▲ 0.01 (0.04%)
TRG 72.63 Increased By ▲ 0.88 (1.23%)
WAVES 10.70 Increased By ▲ 0.72 (7.21%)
WTL 1.26 No Change ▼ 0.00 (0%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published April 13, 2021 Updated April 13, 2021 08:29pm
By

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed for this article.